rct
2021
High Quality
Midodrine for the prevention of vasovagal syncope: a randomized clinical trial
Sheldon R, Faris P, Tang A, Ayala-Paredes F, Guzman J, Marquez M, Raj SR
Published in Annals of Internal Medicine, Vol. 174 (10), pp. 1349-1356
Key Findings
Midodrine reduced the proportion of patients with at least one syncope over 12 months (28% vs 43% with placebo).
Conclusions
Midodrine is an effective drug option for recurrent vasovagal syncope in otherwise healthy patients.
Limitations
Modest sample; supine hypertension and adherence issues.
Related Health Concerns
Study Details
Year:2021
Sample Size:133
Duration:52 weeks
Quality Score:8/10
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.